Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

RegulatorySurgeryMedical DevicesSafety Signal

Hologic Recalls BioZorb Markers Due to Patient Complications Risk

The recall of Hologic's BioZorb markers due to patient complications poses significant risks to patient safety and regulatory compliance. This incident could lead to increased scrutiny from regulatory bodies and impact Hologic's market position and reputation in the surgical device sector.

Published: July 2, 2026
Updated: July 2, 2026
Author: Humanexa Intelligence
Therapeutic area: Surgery / Medical Devices
Asset: Hologic
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Asset

Hologic

Indication

Surgery / Medical Devices

Status

Under Review

Signal Score

8.4

Signal assessment

Signal strength

high

Confidence level

high

Signalhigh
Confidencehigh

Strategic implication

The recall of Hologic's BioZorb markers due to patient complications poses significant risks to patient safety and regulatory compliance. This incident could lead to increased scrutiny from regulatory bodies and impact Hologic's market position and reputation in the surgical device sector.

Why it matters

The recall of Hologic's BioZorb markers due to patient complications poses significant risks to patient safety and regulatory compliance. This incident could lead to increased scrutiny from regulatory bodies and impact Hologic's market position and reputation in the surgical device sector.

What changed

Safety Signal

Analysis

Hologic has recalled its BioZorb 3D bioabsorbable markers following reports of patient complications.

The recall of Hologic's BioZorb markers due to patient complications poses significant risks to patient safety and regulatory compliance. This incident could lead to increased scrutiny from regulatory bodies and impact Hologic's market position and reputation in the surgical device sector.

Monitor for further details on the nature of the complications and any regulatory actions taken by the FDA.

Related companies & assets

Assets

  • Hologic →

Sources & Humanexa intelligence

Source links

  • Hologic Recalls BioZorb Markers Due to Patient Complications Risk ↗

Related Humanexa pages

  • Hologic Recalls BioZorb Markers Due to Patient Complications Risk →

Related signals

Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Asset

Glenmark

Indication

Dermatology / Psoriasis

Status

Approved

Signal Score

8.2

Regulatoryhigh signal

FDA Acceptance of Calcipotriene Supplement by Glenmark

The FDA has accepted the supplement application ANDA205772 for Calcipotriene submitted by Glenmark.

July 4, 2026Read signal →
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval

Company

Novartis

Asset

Cosentyx

Indication

Immunology / IL-17

Status

Approved

Signal Score

8.4

Regulatoryhigh signal

FDA Approves Supplemental Application for Cosentyx (Secukinumab)

The FDA has approved a supplemental application for Cosentyx (Secukinumab) submitted by Novartis.

July 4, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.